PainReform Ltd. 2024 Investor Presentation - PRF-110 Post-Operative Pain

PainReform Ltd. presents PRF-110, a novel extended-release ropivacaine formulation for post-operative pain management. The Phase 3-stage biotech candidate demonstrated up to 72 hours of pain relief in clinical studies, addressing a ~$12B market currently dominated by short-acting local anesthetics and opioids. The company has secured patent protection through 2033 and established manufacturing capabilities in the USA.